Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

Expanded HCV Development Presence Includes ANA598 and ANA773 Acting via

Independent but Potentially Complementary Mechanisms

Conference Call Today at 2:00 PM PDT

SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it is resuming clinical investigation of the Toll-Like Receptor-7 (TLR7) mechanism for the treatment of chronic hepatitis C. Based on preclinical pharmacology testing and the results of completed 13-week GLP animal toxicology studies, Anadys has received clearance to initiate a clinical trial of ANA773, the Company's oral TLR7 agonist prodrug, under a clinical trial application (CTA) in the Netherlands. Following initial dosing in healthy volunteers, this trial will explore every-other-day dosing over 28 days in HCV patients. Anadys also continues to enroll patients in a separate Phase I clinical trial of ANA773 in oncology that is ongoing under an IND in the United States.

"In an extensive preclinical program conducted with ANA773, we have previously shown that the profile of immune stimulation resulting from TLR7 activation can be dramatically modulated by altering the schedule of administration," said James Freddo, M.D., Anadys' Chief Medical Officer. "Now, results of toxicology studies employing every-other-day dosing of ANA773 have shown that we can achieve desired levels of immune stimulation sustained over 13 weeks without adverse toxicology findings. The favorable toxicology profile seen to date, coupled with the stable induction of interferon-alpha dependent responses when ANA773 is dosed every other day over 13 weeks, have convinced us that ANA773 has the potential to demonstrate benefit in patients infected with HC
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 IBM (NYSE: IBM ) and ... NCD Challenge , a competition among a number ... of students to find new ways to address the rise ... (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) Illnesses such ...
... bio-pharmaceutical companies lose the ability to communicate externally because ... internal Advocacy groups will become more important to a ... cost effectiveness of care by communicating concepts and arranging ... Since internal Advocacy groups are not known ...
Cached Medicine Technology:IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 2IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 3Pharmaceutical Advocacy Groups Focus on Value-of-Care Initiatives 2
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate ... Today, the business has introduced its new collection of ... promotion. , The new prom outfits are guaranteed to ... lover. They are specially designed for 2015. Anyone who ... should visit its website before Jan. 26, 2015, the ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... 2014 Over 700 toys, that’s what ... communities. That is 700 smiling little faces this holiday ... over $6000 in monetary donations was given to the ... the expenses they incur through the year. Some of ... A Child's Haven , Shrine's Children's Hospitals, Toys for ...
(Date:12/24/2014)... 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... litigation currently underway in Pennsylvania’s Philadelphia Court of Common ... 24, 2014, court documents indicate that 1,183 claims had ... who developed gynecomastia (male breast growth) and other complications ... indicates that this represents an increase of more than ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... The New AfterShingles.com Helps Educate Consumers About Shingles ... The Visiting Nurse Associations of America (VNAA), the ... on Aging (NCOA) today announced the re-launch of ... to help educate consumers about shingles and postherpetic ...
... awareness by exploring solutions to the most common health problem ... The causes and treatments of enlarged prostate will be ... 2009 at 6:30pm at the Doubletree Hotel in Rosemead. Also ... the prostate affects more than half of all men over ...
... AVAILABLE -SEATTLE, March 31 The sister ... mucous causing oxygen loss and brain damage while she ... Center in Edmonds, Wash., has filed suit against three ... Extendicare REIT. Norene McPherson,s 49-year-old sister, Lea Ann, died ...
... March 31 HealthWorldWeb , the premiere Health 2.0 ... appointment of Michael L. Millenson and J.D. Kleinke to the ... in the industry as supporters and advisors strengthens our belief ... 2.0 personalization is a very real need," said Daniel Kogan, ...
... separate cancer from benign mole, scientists say , , TUESDAY, ... melanoma skin cancer and a harmless mole can still ... But scientists say differences in levels of certain genetic ... Melanoma is the deadliest form of skin cancer. Standard ...
... Georgetown University Medical Center (GUMC) have been able to ... cord injury in preclinical studies. , Their research, published ... by Kimberly Byrnes, PhD, shows that inflammation following injury ... damage, and that an experimental agent is able to ...
Cached Medicine News:Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 2Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 3Health News:Elder Abuse Complaint Filed Against Extendicare 2Health News:Elder Abuse Complaint Filed Against Extendicare 3Health News:HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors 2Health News:Gene Screen Could Help Spot Melanoma 2Health News:By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies 2
... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: